SUVEN LIFE SCIENCES : COMPLETION OF PATIENT ENROLLMENT IN GLOBAL PHASE-3 STUDY OF MASUPIRDINE (SUVN-502) FOR AGITATION ASSOCIATED WITH ALZHEIMER'S DEMENTIA (AAD)

• Suven Life Sciences completes patient enrollment in its global Phase-3 clinical study of Masupirdine for Agitation associated with Alzheimer's Dementia (AAD). • Total of 424 patients were randomized, exceeding the designed target of 375 patients. • Last patient last visit (LPLV) is expected by end of December 2026, with database lock by end of March-2027 and topline results anticipated by May 2027. • Impact: Positive (Completion of patient enrollment marks a significant milestone in the development of Masupirdine for Alzheimer's-related agitation.)

Suven Life Sciences Limited

Open attachment

← Back to feed